Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN versus TAB PROFEN.
INDOCIN vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
NSAID
NSAID